iPS細胞（人工多能性幹細胞）の市場規模、シェア、動向分析レポート：由来細胞タイプ別、用途別、最終用途別、地域別、セグメント別予測、2024年～2030年

iPS細胞（人工多能性幹細胞）市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のiPS細胞（人工多能性幹細胞）市場規模は2030年までに33億1,000万米ドルに達し、2024年から2030年までのCAGRは10.21％で成長すると予測されています。

iPS細胞（人工多能性幹細胞）（iPSC）市場は急速に拡大しています。iPS細胞（人工多能性幹細胞）は、白血病、脊髄損傷、心血管疾患、糖尿病などの病気と闘ったり、闘ったりするために身体に不可欠なあらゆる細胞や組織を生成できることが、その利用の主な理由です。

市場拡大を促進するその他の要因としては、研究費の増加、ゲノミクス・イニシアチブの増加、個別化治療におけるゲノム工学の応用の急増などが挙げられます。その結果、iPSCの採用が加速し、市場の収益成長につながった。例えば、2020年10月、Axxam S.p.A.とFUJIFILM Cellular Dynamics, Inc.は、創薬プロセスを推進するための戦略的パートナーシップを発表しました。ターゲット評価、ハイスループットスクリーニング（HTS）、ハイコンテントスクリーニングを可能にする最先端の創薬技術の使用を通じて、このパートナーシップは創薬研究者と科学者にhiPSCベースのアッセイの統合プラットフォームへのアクセスを提供します。

最近のヘルスケア開発と研究への動向は著しく拡大しており、この動向は予測期間中、iPS細胞（人工多能性幹細胞）の需要に大きな影響を与えると予測されます。精密医療におけるヒトiPSC細胞株の応用範囲の拡大や、幹細胞治療応用への重点の高まりは、iPS細胞（人工多能性幹細胞）市場の拡大を促す重要な要因になると予測されます。例えば、両社の共同声明によると、2021年3月、サナバイオテクノロジー社は、富士フイルムセルラーダイナミクス社のiPSCプラットフォームを商業的に利用可能な細胞療法の作製に使用する認可を取得しました。細胞療法は、細胞、組織、臓器など、ヒトの生物学を改善、修正、代替することができます。

COVID-19パンデミック時の研究活動の活発化も、iPSCを用いた研究を後押ししました。さらに、SARS CoV-2感染を管理するための新しい治療法や治療法を発見するための科学者の継続的な努力は、研究ツールとしてのiPSCの必要性を高めています。さらに、iPS細胞（人工多能性幹細胞）は、生理学的に同等なオルガノイドや臓器モデルを作ることができるため、ヒトにおけるウイルス感染の病態生理学の研究に利用することができます。そのため、業界の成長を後押ししています。

さらに、iPS細胞に関連する様々な科学的活動に焦点を当てた産業の成長とともに、政府や商業部門が資金を拡大しており、様々な組織を通じて人々の幹細胞に対する認識も高まっています。しかし、細胞の初期化にかかるコストの高さ、倫理的な懸念、時間のかかるプロセスといった課題が、iPS細胞（人工多能性幹細胞）産業の成長を一定の範囲で阻害しています。さらに、効率の低さ、潜在的な腫瘍リスク、不十分なプログラミングも、iPSC市場の拡大を制限する懸念事項です。

iPS細胞（人工多能性幹細胞）市場レポートハイライト

• 由来細胞タイプ別では、線維芽細胞セグメントが2023年に30.51%の最大シェアを占めました。医療従事者の間で、皮膚問題の潜在的治療法として線維芽細胞への嗜好が高まっていることが、同分野の成長を後押ししています。
• 用途別では、医薬品開発分野が2023年に49.03％の最大シェアを占めました。慢性疾患の蔓延、座りがちなライフスタイルなどが個別化治療の需要を高めており、iPS細胞の助けを借りて医薬品を開発する製薬・バイオテクノロジー企業の関心の高まりが業界の成長を促進しています。
• 最終用途別では、製薬・バイオテクノロジー企業が2023年に59.83％の最大シェアを占めました。このセグメントは、iPS細胞（人工多能性幹細胞）を用いて様々な疾患のための様々な幹細胞製品・技術を製造・開発しているため、市場を独占すると予測されています。
• 2023年には、北米が36.11%と大きなシェアを占めています。これは主に、薬剤研究、毒性試験、疾患モデリングにおける革新的なシステムや技術の利用の増加によるものであり、幹細胞治療がこの地域で受け入れられつつあることが市場を牽引する主な理由です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 iPS細胞（人工多能性幹細胞）市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• iPS細胞（人工多能性幹細胞）市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 iPS細胞（人工多能性幹細胞）市場： 由来細胞タイプ別推定・動向分析

• セグメントダッシュボード
• 世界のiPS細胞（人工多能性幹細胞）市場： 由来細胞タイプ別変動分析
• 世界のiPS細胞（人工多能性幹細胞）市場規模と動向分析、由来細胞タイプ別、2018～2030年
• 肝細胞
• 線維芽細胞
• ケラチノサイト
• 羊膜細胞
• その他

第5章 iPS細胞（人工多能性幹細胞）市場：用途別推定・動向分析

• セグメントダッシュボード
• 世界のiPS細胞（人工多能性幹細胞）市場： 用途変動分析
• 世界のiPS細胞（人工多能性幹細胞）市場規模と動向分析、用途別、2018～2030年
• 医薬品開発
  • 市場推計・予測、2018-2030年
• 組織工学と再生医療
  • 市場推計・予測、2018-2030年
  • 神経学
  • 整形外科
  • 腫瘍学
  • 心血管疾患および心筋梗塞
  • 糖尿病
  • その他
• 毒性学調査
  • 市場推計・予測、2018-2030年
• 疾患モデル
  • 市場推計・予測、2018-2030年

第6章 iPS細胞（人工多能性幹細胞）市場：最終用途別推定・動向分析

• セグメントダッシュボード
• 世界のiPS細胞（人工多能性幹細胞）市場： 最終用途別変動分析
• 世界のiPS細胞（人工多能性幹細胞）市場規模と動向分析、最終用途別、2018～2030年
• 学術研究機関
• 製薬・バイオテクノロジー企業
• その他

第7章 iPS細胞（人工多能性幹細胞）市場：地域別推定・動向分析

• 地域別市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
  • 北米市場推計・予測、2018-2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州市場推計・予測、2018-2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋市場推計・予測、2018-2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカ市場推計・予測、2018-2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ市場推計・予測、2018-2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業/競合の分類
• 戦略マッピング
• 企業市況分析、2023年
• 企業プロファイル/上場企業
  • STEMCELL Technologies Inc.
  • Cellular Engineering Technologies Inc.
  • REPROCELL Inc.
  • Takara Bio, Inc.
  • Axol Bioscience Ltd.
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Astellas Pharma Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 Global induced pluripotent stem cells market, by region, 2018 - 2030 (USD Million)
• Table 3 Global induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 4 Global induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 5 Global induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 6 North America induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
• Table 7 North America induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 8 North America induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 9 North America induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 10 U.S. induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 11 U.S. induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 12 U.S. induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 13 Canada induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 14 Canada induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 15 Canada induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 16 Mexico induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 17 Mexico induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 18 Mexico induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 19 Europe induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
• Table 20 Europe induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 21 Europe induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 22 Europe induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 23 Germany induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 24 Germany induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 25 Germany induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 26 UK induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 27 UK induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 28 UK induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 29 France induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 30 France induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 31 France induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 32 Italy induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 33 Italy induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 34 Italy induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 35 Spain induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 36 Spain induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 37 Spain induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 38 Denmark induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 39 Denmark induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 40 Denmark induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 41 Sweden induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 42 Sweden induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 43 Sweden induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 44 Norway induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 45 Norway induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 46 Norway induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 51 China induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 52 China induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 53 China induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 54 Japan induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 55 Japan induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 56 Japan induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 57 India induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 58 India induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 59 India induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 60 South Korea induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 61 South Korea induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 62 South Korea induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 63 Australia induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 64 Australia induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 65 Australia induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 66 Thailand induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 67 Thailand induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 68 Thailand induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 69 Latin America induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
• Table 70 Latin America induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 71 Latin America induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 72 Latin America induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 73 Brazil induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 74 Brazil induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 75 Brazil induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 76 Argentina induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 77 Argentina induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 78 Argentina induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 79 MEA induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
• Table 80 MEA induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 81 MEA induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 82 MEA induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 83 South Africa induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 84 South Africa induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 85 South Africa induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 89 UAE induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 90 UAE induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 91 UAE induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
• Table 92 Kuwait induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
• Table 93 Kuwait induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
• Table 94 Kuwait induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market formulation & validation
• Fig. 4 Induced pluripotent stem cells market: Market outlook
• Fig. 5 Induced pluripotent stem cells market: Segment outlook
• Fig. 6 Induced pluripotent stem cells market: Competitive landscape outlook
• Fig. 7 Parent market outlook
• Fig. 8 Induced pluripotent stem cells market driver impact
• Fig. 9 Induced pluripotent stem cells market restraint impact
• Fig. 10 Induced pluripotent stem cells market: Type outlook and key takeaways
• Fig. 11 Induced pluripotent stem cells market: Type movement analysis
• Fig. 12 Hepatocytes market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 13 Fibroblasts market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 14 Keratinocytes market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 Amniotic cells market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Induced pluripotent stem cells market: Application outlook and key takeaways
• Fig. 18 Induced pluripotent stem cells market: Application movement analysis
• Fig. 19 Drug development market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Tissue engineering & regenerative medicine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Neurology market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 22 Orthopedics market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 23 Oncology market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 24 Cardiovascular and myocardial infarction market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 25 Diabetes market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 26 Others market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 27 Toxicology research market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 28 Disease modeling market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 29 Induced pluripotent stem cells market: End use outlook and key takeaways
• Fig. 30 Induced pluripotent stem cells market: End use movement analysis
• Fig. 31 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Global induced pluripotent stem cells market: Regional outlook and key takeaways
• Fig. 35 Global induced pluripotent stem cells market: Regional movement analysis
• Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Key country dynamics
• Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Key country dynamics
• Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Key country dynamics
• Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Key country dynamics
• Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Key country dynamics
• Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Key country dynamics
• Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Key country dynamics
• Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Key country dynamics
• Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Key country dynamics
• Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Key country dynamics
• Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Key country dynamics
• Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Key country dynamics
• Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Key country dynamics
• Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.31 billion by 2030, registering to grow at a CAGR of 10.21% from 2024 to 2030 according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report Highlights:

• By derived cell type, the fibroblasts segment accounted for the largest share of 30.51% in 2023. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
• By application, the drug developmentsegment accounted for the largest share of 49.03% in 2023. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
• By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.83% in 2023. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
• North America held the larger share of 36.11% in 2023. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Derived Cell Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Induced Pluripotent Stem Cells Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Increasing research and development activities in stem cell therapies
    • 3.2.1.3. Growing adoption of personalized medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
• 3.3. Induced Pluripotent Stem Cells Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Induced Pluripotent Stem Cells Market: Derived Cell Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Induced Pluripotent Stem Cells Market Derived Cell Type Movement Analysis
• 4.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Derived Cell Type, 2018 to 2030 (USD Million)
• 4.4. Hepatocytes
  • 4.4.1. Hepatocytes market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Fibroblasts
  • 4.5.1. Fibroblasts market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Keratinocytes
  • 4.6.1. Keratinocytes market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Amniotic Cells
  • 4.7.1. Amniotic cells market estimates and forecasts 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Induced Pluripotent Stem Cells Market Application Movement Analysis
• 5.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Drug Development
  • 5.4.1. Drug development market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Tissue Engineering & Regenerative Medicine
  • 5.5.1. Tissue engineering & regenerative medicine market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.2. Neurology
    • 5.5.2.1. Neurology market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.3. Orthopedics
    • 5.5.3.1. Orthopedics market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.4. Oncology
    • 5.5.4.1. Oncology market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.5. Cardiovascular & Myocardial Infarction
    • 5.5.5.1. Cardiovascular & myocardial infarction market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.6. Diabetes
    • 5.5.6.1. Diabetes market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.7. Others
    • 5.5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Toxicology Research
  • 5.6.1. Toxicology research market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Disease Modeling
  • 5.7.1. Disease modeling market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Induced Pluripotent Stem Cells Market End Use Movement Analysis
• 6.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
• 6.4. Academic & Research Institutes
  • 6.4.1. Academic & research institutes market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical & Biotechnology Companies
  • 6.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Target disease prevalence
    • 7.4.2.5. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Target disease prevalence
    • 7.4.3.5. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Target disease prevalence
    • 7.4.4.5. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Target disease prevalence
    • 7.5.4.5. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Target disease prevalence
    • 7.5.5.5. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Target disease prevalence
    • 7.5.6.5. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Target disease prevalence
    • 7.5.7.5. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Target disease prevalence
    • 7.5.8.5. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Target disease prevalence
    • 7.5.9.5. Norway market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Target disease prevalence
    • 7.6.7.5. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Target disease prevalence
    • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Target disease prevalence
    • 7.8.4.5. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Target disease prevalence
    • 7.8.5.5. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Company Profiles/Listing
  • 8.4.1. STEMCELL Technologies Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cellular Engineering Technologies Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. REPROCELL Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Takara Bio, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Axol Bioscience Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Fate Therapeutics, Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. FUJIFILM Cellular Dynamics, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Cynata Therapeutics Limited
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Evotec SE
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Astellas Pharma Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives